Key Takeaways
- MYCOPHYTO has finalized a €16 million Series A funding round.
- The round was led by Innovacom, BNP Paribas, and Bpifrance’s Deep Tech 2030 fund.
- New and existing investors include CDG Invest, Noshaq, RSI, and Crédit Agricole.
- The funding will support MYCOPHYTO’s first production facility and international expansion.
- MYCOPHYTO develops AI-formulated mycorrhizal biostimulants to improve crop resilience and soil health.
MYCOPHYTO Secures €16 Million Series A Funding Round
MYCOPHYTO has announced the completion of a €16 million Series A funding round to support its next phase of growth and accelerate its international ambitions. The round was led by Innovacom, BNP Paribas, and the Deep Tech 2030 fund managed by Bpifrance on behalf of the French State as part of the France 2030 initiative.
The financing also includes participation from CDG Invest and Noshaq, alongside renewed support from existing shareholders RSI and Crédit Agricole. According to the company, the Series A marks a major milestone in transitioning from early commercial traction to industrial-scale deployment.
Scaling Production and Expanding Internationally
With the new capital, MYCOPHYTO plans to significantly increase its production capacity through the construction of its first industrial facility. The future plant will integrate sustainable technologies and benefits from state-backed support following MYCOPHYTO’s selection under the France 2030 call for projects “Résilience et capacités agroalimentaires 2030.”
In parallel, MYCOPHYTO aims to accelerate its international development. Current operations in Spain and Morocco will be reinforced, while new agricultural value chains are expected to emerge in additional regions including Côte d’Ivoire and the Benelux.
Justine Lipuma, CEO and co-founder of MYCOPHYTO, said, “This Series A represents a decisive step in our development and gives us the means to accelerate our expansion and strengthen our international ambition.”
Technology Addressing Climate and Soil Challenges
Founded in 2017, MYCOPHYTO supports farmers in their agroecological transition through mycorrhizal biostimulant solutions inspired by natural soil biology. Mycorrhizal fungi form symbiotic relationships with plant roots, improving access to water and nutrients, particularly under conditions of drought or soil degradation.
MYCOPHYTO has developed a proprietary production process, supported by artificial intelligence, to formulate fungal consortia adapted to specific soil and climatic conditions. According to the company, its solutions have demonstrated up to 20% improvements in plant water retention and maintained or increased yields during drought periods. In viticulture, yield increases of up to 45% have been measured across multiple growing seasons, alongside more efficient fertilizer use.
Investor Perspectives and Long-Term Positioning For Mycophyto
Investors involved in the Series A highlighted MYCOPHYTO’s combination of scientific depth, industrial readiness, and market traction. Representatives from Innovacom and Bpifrance pointed to the company’s role in addressing food sovereignty and climate resilience, while BNP Paribas emphasized the differentiated nature of MYCOPHYTO’s R&D-driven approach to soil regeneration.
MYCOPHYTO stated that the Series A funding positions the company to move into large-scale production, expand internationally, and further establish itself as a reference player in regenerative and climate-resilient agriculture.
1 Comment